Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients.
Serum tetranectin (Se-TN) and CA-125 were measured in serum samples obtained before primary surgery, before start of chemotherapy and monthly during chemotherapy in 8 patients with ovarian cancer. The median Se-TN level before chemotherapy (7.3 mg/l) increased significantly after the start of chemotherapy (13.7 mg/l), with the highest increase for one survivor (145%). Five patients who died of cancer in the study period, had pronounced decreases (30-50%) in Se-TN with a maximal concentration during chemotherapy to the lowest concentration in the last sample. One patient who died 10 months after closure of the study had continuously normal Se-TN values, but the last CA-125 value elevated. The lead time could be calculated in four patients for Se-TN and six patients for CA-125. Median lead times of 3.6 months and 3.8 months were found for Se-TN and CA-125 respectively. In conclusion, chemotherapy induces significant increases in Se-TN levels. A decrease in Se-TN during chemotherapy is highly suspect for recurrence and a poor outcome. Measurements of TN should therefore be included in other comparative studies.
Høgdall
C K
CK
Department of Clinical Biochemistry, Statens Seruminstitut, Copenhagen, Denmark.
Hørding
U
U
Nørgaard-Pedersen
B
B
Toftager-Larsen
K
K
Clemmensen
I
I
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins / Q000032:analysis*; D018394:CA-125 Antigen / Q000097:blood*; D003131:Combined Modality Therapy; D016903:Drug Monitoring; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D037181:Lectins, C-Type; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000601:surgery; D015996:Survival Rate; D013997:Time Factors
D014408:Biomarkers, Tumor; D001798:Blood Proteins; D018394:CA-125 Antigen; D037181:Lectins, C-Type; C048648:tetranectin